慢性前列腺炎/慢性盆腔疼痛综合征的药物治疗:Cochrane系统综述
该Cochrane系统综述纳入99项随机对照试验、共9119名CP/CPPS男性患者,评估16类药物的疗效与安全性。低至极低质量证据显示α受体阻滞剂可能减轻前列腺炎症状但增加头晕和低血压等轻微不良事件;5α还原酶抑制剂、抗生素、抗炎药和植物疗法可能小幅改善症状且不增加不良事件;抗胆碱能药、大肠埃希菌裂解物、戊聚糖和普瑞巴林可能无效。
要点
- α受体阻滞剂可能降低NIH-CPSI评分>2但<8分,但增加头晕和低血压风险。
- 5α还原酶抑制剂、抗生素、抗炎药和植物疗法可能小幅改善症状,不增加不良事件。
- 抗胆碱能药、大肠埃希菌裂解物、戊聚糖和普瑞巴林可能无效。
核心结论
- 基于低至极低质量证据,α受体阻滞剂可能减轻CP/CPPS症状但增加轻微不良事件。
- 部分药物可能减轻症状且不增加不良事件,另一些药物则无效。
研究设计与样本
- Cochrane系统综述,检索多个数据库、试验注册库、灰色文献和会议论文集,最新检索日期为2019年7月,无语言或发表状态限制。
- 纳入99项随机对照试验,共9119名诊断为CP/CPPS的男性,评估16类药理干预。
- 采用GRADE方法评价证据质量,主要结局为前列腺炎症状和不良事件。
主要发现
- α受体阻滞剂可能降低NIH-CPSI评分>2但<8分,增加头晕和低血压等轻微不良事件(低至极低质量证据)。
- 5α还原酶抑制剂、抗生素、抗炎药和植物疗法可能小幅减轻症状,不增加不良事件(中至低质量证据)。
- 前列腺内注射A型肉毒毒素可能大幅减轻症状但伴血尿等操作相关不良事件;盆底肌注射可能无效(低质量证据)。
- 别嘌醇可能无效(低质量证据);传统中药可能减轻症状且不增加不良事件(低质量证据)。
- 抗胆碱能药、大肠埃希菌裂解物(OM-89)、戊聚糖和普瑞巴林可能无效(中至高质量证据);抗抑郁药和他尼珠单抗可能无效(低至极低质量证据)。
关键数值与推荐
- α受体阻滞剂:NIH-CPSI评分降低>2但<8分,不良事件增加。
- 5α还原酶抑制剂、抗生素、抗炎药和植物疗法:症状小幅减轻,不良事件不增加。
- 前列腺内BTA注射:症状大幅减轻,伴血尿;盆底肌BTA注射可能无效。
- 抗胆碱能药、OM-89、戊聚糖和普瑞巴林:可能无效(中至高质量证据)。
临床怎么用
- α受体阻滞剂可用于CP/CPPS症状控制,但需监测头晕和低血压。
- 5α还原酶抑制剂、抗生素、抗炎药和植物疗法可作为症状改善选项,不良事件风险较低。
- 避免使用抗胆碱能药、OM-89、戊聚糖和普瑞巴林等可能无效的药物。
局限性
- 多数研究随访期短。
- 多数研究未说明资金来源,21项研究由制药公司资助。
- 多数比较的证据质量低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effects of pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). PATIENTS AND METHODS: We performed a comprehensive search using multiple databases, trial registries, grey literature and conference proceedings with no restrictions on the language of publication or publication status. The date of the latest search of all databases was July 2019. We included randomised controlled trials. Inclusion criteria were men with a diagnosis of CP/CPPS. We included all available pharmacological interventions. Two review authors independently classified studies and abstracted data from the included studies, performed statistical analyses and rated quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods. The primary outcomes were prostatitis symptoms and adverse events. The secondary outcomes were sexual dysfunction, urinary symptoms, quality of life, anxiety and depression. RESULTS: We included 99 unique studies in 9119 men with CP/CPPS, with assessments of 16 types of pharmacological interventions. Most of our comparisons included short-term follow-up information. The median age of the participants was 38 years. Most studies did not specify their funding sources; 21 studies reported funding from pharmaceutical companies. We found low- to very low-quality evidence that α-blockers may reduce prostatitis symptoms based on a reduction in National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) scores of >2 (but <8) with an increased incidence of minor adverse events such as dizziness and hypotension. Moderate- to low-quality evidence indicates that 5α-reductase inhibitors, antibiotics, anti-inflammatories, and phytotherapy probably cause a small decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse events. Intraprostatic botulinum toxin A (BTA) injection may cause a large reduction in prostatitis symptoms with procedure-related adverse events (haematuria), but pelvic floor muscle BTA injection may not have the same effects (low-quality evidence). Allopurinol may also be ineffective for reducing prostatitis symptoms (low-quality evidence). We assessed a wide range of interventions involving traditional Chinese medicine; low-quality evidence showed they may reduce prostatitis symptoms without an increased incidence in adverse events. Moderate- to high-quality evidence indicates that the following interventions may be ineffective for the reduction of prostatitis symptoms: anticholinergics, Escherichia coli lysate (OM-89), pentosan, and pregabalin. Low- to very low-quality evidence indicates that antidepressants and tanezumab may be ineffective for the reduction of prostatitis symptoms. Low-quality evidence indicates that mepartricin and phosphodiesterase inhibitors may reduce prostatitis symptoms, without an increased incidence in adverse events. CONCLUSIONS: Based on the findings of low- to very low-quality evidence, this review found that some pharmacological interventions such as α-blockers may reduce prostatitis symptoms with an increased incidence of minor adverse events such as dizziness and hypotension. Other interventions may cause a reduction in prostatitis symptoms without an increased incidence of adverse events while others were found to be ineffective.
引用
- Franco JVA, Turk T, Jung JH, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2020. PMID: 31899937. doi:10.1111/bju.14988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。